BioSpace News Archive

CytoSorbents Corporation announces the full approval of its Investigational Device Exemption application to conduct the pivotal STAR-T double-blind, randomized, controlled trial in the United States to support FDA regulatory clearance.

4D pharma plc today announces the publication of pre-clinical research relating to its second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T.

Immunome, Inc. today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021, at 10:30 a.m. ET.

CinCor Pharma, Inc. announced the appointment of Marc de Garidel, currently on the Company’s Board of Directors, as Chief Executive Officer, effective immediately.

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in one-on-one investor meetings at the upcoming William Blair Biotech Focus Conference 2021,

Molecular Templates, Inc. announced that it will provide a corporate update and participate in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to take place July 13-14, 2021.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced it has reached the target enrollment in the phase 3 PaTHway Trial, a trial evaluating the safety, tolerability, and efficacy of TransCon PTH (palopegteriparatide) in addition to providing a comprehensive global clinical program update.

Lipocine Inc. today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has executed a contract for ZYNRELEF with Apexus, LLC (Apexus).

BioHarvest Sciences Inc. (CSE: BHSC) (the “Company”, “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, July 8, 2021, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).